1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cardiovascular Outcomes Associated with Lowering Low-density Lipoprotein Cholesterol in Rheumatoid Arthritis and Matched Nonrheumatoid Arthritis.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To examine the associations between lowering low-density lipoprotein cholesterol (LDL-C) and cardiovascular (CV) outcomes among patients with rheumatoid arthritis (RA) and patients without it.

          Related collections

          Author and article information

          Journal
          J. Rheumatol.
          The Journal of rheumatology
          The Journal of Rheumatology
          0315-162X
          0315-162X
          Nov 2016
          : 43
          : 11
          Affiliations
          [1 ] From the Department of Pharmacy Practice and Administration, Western University of Health Sciences, Pomona, California; Bristol-Myers Squibb, Princeton, New Jersey; Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California; Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Drug Information Services, Kaiser Permanente Southern California, Downey, California, USA. jan@westernu.edu.
          [2 ] J. An, BPharm, PhD, Department of Pharmacy Practice and Administration, Western University of Health Sciences; E. Alemao, RPh, MS, Bristol-Myers Squibb; K. Reynolds, PhD, MPH, Research and Evaluation, Kaiser Permanente Southern California; H. Kawabata, MS, Bristol-Myers Squibb; D.H. Solomon, MD, MPH, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School; K.P. Liao, MD, MPH, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School; F. Niu, MS, Drug Information Services, Kaiser Permanente Southern California; T.C. Cheetham, PharmD, MS, Research and Evaluation, Kaiser Permanente Southern California. jan@westernu.edu.
          [3 ] From the Department of Pharmacy Practice and Administration, Western University of Health Sciences, Pomona, California; Bristol-Myers Squibb, Princeton, New Jersey; Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California; Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Drug Information Services, Kaiser Permanente Southern California, Downey, California, USA.
          [4 ] J. An, BPharm, PhD, Department of Pharmacy Practice and Administration, Western University of Health Sciences; E. Alemao, RPh, MS, Bristol-Myers Squibb; K. Reynolds, PhD, MPH, Research and Evaluation, Kaiser Permanente Southern California; H. Kawabata, MS, Bristol-Myers Squibb; D.H. Solomon, MD, MPH, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School; K.P. Liao, MD, MPH, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School; F. Niu, MS, Drug Information Services, Kaiser Permanente Southern California; T.C. Cheetham, PharmD, MS, Research and Evaluation, Kaiser Permanente Southern California.
          Article
          jrheum.160110
          10.3899/jrheum.160110
          27585690
          f0561c8f-236b-40ba-97e6-1390612807a8
          History

          CARDIOVASCULAR DISEASES,CHOLESTEROL,LOW-DENSITY LIPOPROTEIN,RHEUMATOID ARTHRITIS

          Comments

          Comment on this article